Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C

By Tohra S.  

Digestive Diseases and Sciences, Vol. 56, Iss. 8, 2011-08 ,pp. : 2449-2455

Springer Publishing Company

Access to resources Recommend Favorite

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

By Takaki Shintaro   Tsubota Akihito   Hosaka Tetsuya   Akuta Norio   Someya Takashi   Kobayashi Masahiro   Suzuki Fumitaka   Suzuki Yoshiyuki   Saitoh Satoshi   Arase Yasuji   Ikeda Kenji   Kumada Hiromitsu  

Journal of Gastroenterology, Vol. 39, Iss. 7, 2004-07 ,pp. : 668-673

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of Interferon Alfa-2b With and Without Ribavirin as Therapy for Chronic Hepatitis C in Sweden

By Sennfält K.   Reichard O.   Hultkrantz R.   Wong J. B.   Jonsson D.  

Scandinavian Journal of Gastroenterology, Vol. 36, Iss. 8, 2001-08 ,pp. : 870-876

Informa Healthcare

Access to resources Recommend Favorite

From Trials to a Real Hospital Setting: Effectiveness of Pegylated Interferon-α-2b/Ribavirin Combination Therapy for Naïve Chronic Hepatitis C Patients

By Piai Guido   Scalice Elisa   Focareta Rosaria   Terracciano Fulvia   Filippo Francesca   Forte Giovambattista  

Digestive Diseases and Sciences, Vol. 51, Iss. 9, 2006-09 ,pp. : 1619-1626

Springer Publishing Company

Access to resources Recommend Favorite

Prediction of Response to Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C Genotypes 2a and 2b and High Viral Load

By  

Digestive Diseases, Vol. 31, Iss. 5-6, 2013-11 ,pp. : 426-433

Karger

Access to resources Recommend Favorite